BMO Capital analyst Evan Seigerman notes that a U.S. district court issued a ruling in favor of Acadia Pharmaceuticals (ACAD) in their Nuplazid patent infringement lawsuit with Aurobindo, confirming today that Aurobindo infringed on claims 4 and 5 of Acadia’s 11,452,721 U.S. formulation patent. Today’s announcement likely extends the lifespan of pimavanserin and could extend the company’s patent protection from 2030 to 2038, removing a “key overhang,” says the analyst, who reiterates an Outperform rating and $24 price target on Acadia shares.
Kens
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$17.12 |
Change
0.490(2.95%) |
Mkt cap ! $2.155B | |||
| Open | High | Low | Value | Volume |
| $16.80 | $17.17 | $16.63 | $2.449M | 145.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 83 | $17.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.13 | 207 | 5 |
View Market Depth
| Last trade - 11.45am 31/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |